Share on LinkedInShare on LinkedIn

ARTICLE · 14 MARCH 2019

Biologic Patent Transparency Act - New Bill Aimed At Biologics

A bipartisan group of senators sponsored a bill this week—the Biologic Patent Transparency Act, S. 659—aimed at making patent information associated with biologics easier to identify and easing the approval process ...

United StatesIntellectual Property

A bipartisan group of senators sponsored a bill this week—the Biologic Patent Transparency Act, S. 659—aimed at making patent information associated with biologics easier to identify and easing the approval process for biosimilar manufacturers encountering patent roadblocks.

The bill tracks some key provisions of the Hatch-Waxman Act. Notably, it requires the holders of an approved biologic product to submit a list of patents associated with the biologic within 30 days of approval. If a new patent is issued, the list must be updated within 30 days. And, the bill would apply retroactively: within 30 days of enactment, the holders of previously-approved biologic products must submit patent lists. The patents required to be disclosed are those for which the holder believes a claim of patent infringement could reasonably be asserted. This is notably broader than the equivalent requirement in the Hatch-Waxman Act, as it includes manufacturing processes as well. If a

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from